Mito-Extra (Mitomycin)

• Mitomycin is used as a local chemotherapeutic agent for urothelial malignancies.
• Non‑muscle invasive bladder cancer: reduces tumour recurrence and progression after transurethral resection.
• Bladder carcinoma in situ: provides direct cytotoxic effect to eradicate residual malignant cells.
• Superficial bladder cancer: helps prevent new tumor development following endoscopic surgery.

• Mitomycin enters urothelial cells and undergoes enzymatic reduction to generate reactive intermediates that form covalent cross‑links between DNA strands. These cross‑links inhibit DNA replication and transcription, leading to cell cycle arrest and apoptosis of rapidly dividing cancer cells within the bladder wall.

Mitomycin administered intravesically can cause both local and systemic adverse reactions.

Common Side Effects

• Bladder irritation or burning sensation during or after instillation.
• Dysuria and increased urinary frequency.
• Hematuria or mild blood in urine.
• Nausea or mild gastrointestinal upset.
• Transient fatigue or weakness.
• Mild systemic absorption leading to low‑grade myelosuppression.

Serious or Rare Side Effects

• Severe chemical cystitis with intense pain and ulceration.
• Bladder perforation during instillation.
• Significant bone‑marrow suppression causing neutropenia or thrombocytopenia.
• Systemic allergic or anaphylactic reactions.
• Renal toxicity or acute kidney injury.
• Secondary malignancies with long‑term exposure.

• Before using Mitomycin intravesically, clinicians should observe several safety measures.
• Dose individualized by prescriber: follow the specific regimen ordered for each patient.
• Renal function monitoring: assess serum creatinine and eGFR before each cycle.
• Hematologic surveillance: perform complete blood counts to detect myelosuppression.
• Avoid in active urinary infection: treat infection prior to instillation.
• Pregnancy and lactation: safety unknown; avoid use in pregnant or breastfeeding patients.
• Store at room temperature: keep in original container, protect from moisture and light.

Mitomycin may interact with other agents that affect the bladder or systemic toxicity.

Major Interactions (Avoid)

• Concomitant intravesical alkylating agents: additive bladder toxicity.
• Systemic chemotherapy with myelosuppressive drugs: heightened bone‑marrow suppression.
• Nephrotoxic medications (e.g., aminoglycosides): increased risk of renal injury.
• Pelvic radiotherapy performed concurrently: amplified urothelial damage.
• Live vaccines if systemic absorption occurs: risk of infection.

Moderate Interactions (Monitor Closely)

• CYP450 substrates metabolized hepatically: possible altered plasma levels.
• Anticoagulants (warfarin, DOACs): monitor for bleeding due to mucosal irritation.
• NSAIDs: watch renal function and urinary irritation.
• Diuretics: may affect bladder concentration of drug.
• ACE inhibitors or ARBs: monitor renal parameters during therapy.